NeoGenomics, Inc. (NEO): Price and Financial Metrics


NeoGenomics, Inc. (NEO): $11.62

0.45 (+4.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NEO POWR Grades

  • NEO scores best on the Growth dimension, with a Growth rank ahead of 87.13% of US stocks.
  • The strongest trend for NEO is in Stability, which has been heading up over the past 179 days.
  • NEO ranks lowest in Value; there it ranks in the 10th percentile.

NEO Stock Summary

  • NEO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1.5 -- higher than 25.98% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, NEOGENOMICS INC is reporting a growth rate of -511.58%; that's higher than only 3.39% of US stocks.
  • In terms of volatility of its share price, NEO is more volatile than 82.71% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NEOGENOMICS INC are AMRN, CDXC, OYST, STIM, and EVER.
  • Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to www.neogenomics.com.

NEO Valuation Summary

  • NEO's price/sales ratio is 2.6; this is 30% higher than that of the median Healthcare stock.
  • Over the past 228 months, NEO's price/earnings ratio has gone up 6.8.

Below are key valuation metrics over time for NEO.

Stock Date P/S P/B P/E EV/EBIT
NEO 2022-11-25 2.6 1.3 -7.9 -9.4
NEO 2022-11-23 2.6 1.3 -8.0 -9.5
NEO 2022-11-22 2.6 1.3 -7.9 -9.4
NEO 2022-11-21 2.6 1.3 -7.9 -9.4
NEO 2022-11-18 2.6 1.3 -7.9 -9.4
NEO 2022-11-17 2.5 1.2 -7.7 -9.2

NEO Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -1132.5%.
  • Its 2 year cash and equivalents growth rate is now at 254.65%.
  • The 5 year cash and equivalents growth rate now stands at 588.65%.
Over the past 70 months, NEO's revenue has gone up $252,672,000.

The table below shows NEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 496.755 -82.084 -163.322
2022-06-30 489.313 -73.579 -146.818
2022-03-31 485.965 -57.973 -35.642
2021-12-31 484.329 -26.723 -8.347
2021-09-30 484.594 -0.962 48.828
2021-06-30 488.698 7.331 71.733

NEO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NEO has a Quality Grade of C, ranking ahead of 30.23% of graded US stocks.
  • NEO's asset turnover comes in at 0.366 -- ranking 397th of 561 Business Services stocks.
  • MSFT, VRNS, and SGRP are the stocks whose asset turnover ratios are most correlated with NEO.

The table below shows NEO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.366 0.422 0.085
2021-03-31 0.414 0.399 -0.033
2020-12-31 0.490 0.418 -0.014
2020-09-30 0.508 0.419 -0.033
2020-06-30 0.522 0.433 -0.042
2020-03-31 0.589 0.468 0.016

NEO Price Target

For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $56.80 Average Broker Recommendation 1.25 (Strong Buy)

NEO Stock Price Chart Interactive Chart >

Price chart for NEO

NEO Price/Volume Stats

Current price $11.62 52-week high $35.40
Prev. close $11.17 52-week low $6.00
Day low $10.85 Volume 1,068,400
Day high $11.65 Avg. volume 1,719,007
50-day MA $8.76 Dividend yield N/A
200-day MA $10.73 Market Cap 1.47B

NeoGenomics, Inc. (NEO) Company Bio


NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.


NEO Latest News Stream


Event/Time News Detail
Loading, please wait...

NEO Latest Social Stream


Loading social stream, please wait...

View Full NEO Social Stream

Latest NEO News From Around the Web

Below are the latest news stories about NEOGENOMICS INC that investors may wish to consider to help them evaluate NEO as an investment opportunity.

RaDaR(R) Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease

NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, and its liquid biopsy-focused subsidiary, Inivata Limited ("Inivata") today announced that new data, being presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, support the use of the RaDaR®Assay across all types of early breast cancer in both the adjuvant and surveillance settings.

Yahoo | November 21, 2022

NeoGenomics and ImmunoGen Launch New Program Giving Ovarian Cancer Patients Access to Novel FR Biomarker Testing to Support the Launch of ELAHERE(TM)

NeoGenomics, Inc. (NASDAQ:NEO),a leading provider of oncology testing and global contract research services, today launched a novel biomarker testing program for patients with epithelial ovarian cancer, including primary peritoneal or fallopian tube cancers (EOC).Through the FR-ASSIST™ program, sponsored by ImmunoGen, Inc., (Nasdaq:IMGN), EOC patients will have access to the FOLR1 IHC CDx test (VENTANA FOLR1 RxDx Assay) performed by NeoGenomics to

Yahoo | November 18, 2022

NeoGenomics (NEO) Receives a Buy from Raymond James

Raymond James analyst Andrew Cooper maintained a Buy rating on NeoGenomics (NEO - Research Report) today and set a price target of $12.00. The company's shares closed yesterday at $10.08.According to TipRanks, Cooper is an analyst with an average return of -21.5% and a 27.08% success rate. Cooper covers the Healthcare sector, focusing on stocks such as LumiraDx, Exact Sciences, and Haemonetics.In addition to Raymond James, NeoGenomics also received a Buy from Goldman Sachs's Matthew Sykes in a report issued on November 9. However, on the same day, Morgan Stanley maintained a Hold rating on NeoGenomics (NASDAQ: NEO).

Jason Carr on TipRanks | November 11, 2022

Why Shares of NeoGenomics Jumped 53.9% This Week

The cancer screening company showed its turnaround may be working.

The Motley Fool | November 11, 2022

NeoGenomics Third Quarter 2022 Earnings: Beats Expectations

NeoGenomics ( NASDAQ:NEO ) Third Quarter 2022 Results Key Financial Results Revenue: US$128.8m (up 6.1% from 3Q 2021...

Yahoo | November 11, 2022

Read More 'NEO' Stories Here

NEO Price Returns

1-mo 58.31%
3-mo 18.57%
6-mo 43.99%
1-year -64.07%
3-year -54.56%
5-year 27.27%
YTD -65.94%
2021 -36.63%
2020 84.07%
2019 131.96%
2018 42.33%
2017 3.38%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7939 seconds.